JP2017503505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503505A5 JP2017503505A5 JP2016545811A JP2016545811A JP2017503505A5 JP 2017503505 A5 JP2017503505 A5 JP 2017503505A5 JP 2016545811 A JP2016545811 A JP 2016545811A JP 2016545811 A JP2016545811 A JP 2016545811A JP 2017503505 A5 JP2017503505 A5 JP 2017503505A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- helix
- fragment
- residues
- fusion polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- 229920001184 polypeptide Polymers 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims description 43
- 101001002466 Homo sapiens Interferon lambda-3 Proteins 0.000 claims description 43
- 102100020990 Interferon lambda-1 Human genes 0.000 claims description 43
- 102100020992 Interferon lambda-3 Human genes 0.000 claims description 43
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 40
- 102000001708 Protein Isoforms Human genes 0.000 claims description 33
- 108010029485 Protein Isoforms Proteins 0.000 claims description 33
- 108010050904 Interferons Proteins 0.000 claims description 17
- 102000014150 Interferons Human genes 0.000 claims description 17
- 230000001747 exhibiting effect Effects 0.000 claims description 17
- 229940079322 interferon Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 102220577380 Ras-related protein Rab-22A_Q64L_mutation Human genes 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102220335304 rs1555833051 Human genes 0.000 claims description 3
- 241000801930 Apterona helix Species 0.000 claims description 2
- 102220526454 DNA (cytosine-5)-methyltransferase 3B_R54P_mutation Human genes 0.000 claims description 2
- 102220477327 Protein XRP2_Q31A_mutation Human genes 0.000 claims description 2
- 102220612026 Tyrosine-protein kinase Fer_K37R_mutation Human genes 0.000 claims description 2
- 102220415904 c.104G>A Human genes 0.000 claims description 2
- 102220351305 c.176C>A Human genes 0.000 claims description 2
- 102220355148 c.260A>G Human genes 0.000 claims description 2
- 102220354823 c.28G>C Human genes 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102200091760 rs1043302 Human genes 0.000 claims description 2
- 102200012566 rs111033665 Human genes 0.000 claims description 2
- 102200039507 rs121918314 Human genes 0.000 claims description 2
- 102220068389 rs201989984 Human genes 0.000 claims description 2
- 102220005490 rs33986902 Human genes 0.000 claims description 2
- 102220005375 rs34269448 Human genes 0.000 claims description 2
- 102220178418 rs367835995 Human genes 0.000 claims description 2
- 102220219140 rs398123324 Human genes 0.000 claims description 2
- 102220047519 rs587777841 Human genes 0.000 claims description 2
- 102220045411 rs587782084 Human genes 0.000 claims description 2
- 102220032023 rs72554321 Human genes 0.000 claims description 2
- 102200101793 rs72554337 Human genes 0.000 claims description 2
- 102220056958 rs730880941 Human genes 0.000 claims description 2
- 102200142361 rs79011243 Human genes 0.000 claims description 2
- 102220072337 rs794728990 Human genes 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 102220484957 Olfactory receptor 4M2_G96E_mutation Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/070328 WO2015103749A1 (en) | 2014-01-08 | 2014-01-08 | Fusion polypeptides and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019039348A Division JP2019107021A (ja) | 2019-03-05 | 2019-03-05 | 融合ポリペプチドおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503505A JP2017503505A (ja) | 2017-02-02 |
| JP2017503505A5 true JP2017503505A5 (enExample) | 2017-03-09 |
| JP6730926B2 JP6730926B2 (ja) | 2020-07-29 |
Family
ID=53523446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545811A Active JP6730926B2 (ja) | 2014-01-08 | 2014-01-08 | 融合ポリペプチドおよび使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10246501B2 (enExample) |
| EP (2) | EP3092248B1 (enExample) |
| JP (1) | JP6730926B2 (enExample) |
| CN (2) | CN104968673B (enExample) |
| WO (1) | WO2015103749A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104968673B (zh) | 2014-01-08 | 2018-11-02 | 德益阳光生物技术（北京）有限责任公司 | 融合多肽及使用方法 |
| KR20190062490A (ko) | 2016-09-30 | 2019-06-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Iii형 변이체 인터페론 및 신테카인 |
| JP2019107021A (ja) * | 2019-03-05 | 2019-07-04 | プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド | 融合ポリペプチドおよび使用方法 |
| CN112694526B (zh) * | 2020-05-27 | 2023-01-20 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
| US20230265144A1 (en) * | 2020-05-27 | 2023-08-24 | Sciwind Biosciences Co., Ltd. | Interleukin 29 mutant protein |
| CN112870336B (zh) * | 2021-02-24 | 2022-06-14 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白制剂 |
| CN115385998B (zh) * | 2021-04-13 | 2025-08-05 | 杭州先为达生物科技股份有限公司 | 稳定的iii型干扰素蛋白及其融合蛋白 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5939286A (en) * | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| CN100448993C (zh) | 2000-06-30 | 2009-01-07 | 津莫吉尼蒂克斯公司 | 干扰素样蛋白质Zcyto21 |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| ES2303132T3 (es) * | 2003-08-07 | 2008-08-01 | Zymogenetics, Inc. | Preparaciones homogeneas de il-29. |
| GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| CA2574564C (en) * | 2004-07-29 | 2013-04-16 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| CN101031316A (zh) * | 2004-07-29 | 2007-09-05 | 津莫吉尼蒂克斯公司 | Il－28和il－29治疗癌症和自身免疫性疾病的用途 |
| AU2005229674B2 (en) | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
| ATE465176T1 (de) * | 2004-12-09 | 2010-05-15 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| DE602006018969D1 (de) * | 2005-10-04 | 2011-01-27 | Bristol Myers Squibb Co | Herstellung und reinigung von il-29 |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| RU2562108C2 (ru) * | 2007-09-20 | 2015-09-10 | Коммонвелт Сайентифик Энд Индастриал Рисерч Органайзейшн | Новые цитокины птиц и кодирующие их генетические последовательности |
| CA2727026A1 (en) * | 2008-06-05 | 2009-12-10 | Zymogenetics, Llc | Use of pegylated type iii interferons for the treatment of hepatitis c |
| WO2010045261A1 (en) * | 2008-10-13 | 2010-04-22 | Zymogenetics, Llc | Single chain fc type iii interferons and methods of using same |
| EP3604555B1 (en) | 2011-10-14 | 2024-12-25 | President and Fellows of Harvard College | Sequencing by structure assembly |
| WO2013087727A1 (en) * | 2011-12-12 | 2013-06-20 | Institut Pasteur | New efficient interferon-based treating methods |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| CN104968673B (zh) | 2014-01-08 | 2018-11-02 | 德益阳光生物技术（北京）有限责任公司 | 融合多肽及使用方法 |
-
2014
- 2014-01-08 CN CN201480003114.XA patent/CN104968673B/zh active Active
- 2014-01-08 EP EP14877922.6A patent/EP3092248B1/en active Active
- 2014-01-08 EP EP21178199.2A patent/EP3954714A1/en not_active Withdrawn
- 2014-01-08 CN CN201811243025.9A patent/CN109293782A/zh active Pending
- 2014-01-08 JP JP2016545811A patent/JP6730926B2/ja active Active
- 2014-01-08 WO PCT/CN2014/070328 patent/WO2015103749A1/en not_active Ceased
- 2014-01-08 US US15/107,101 patent/US10246501B2/en active Active
-
2019
- 2019-01-18 US US16/252,530 patent/US11242371B2/en active Active